SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YellowLegalPad
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy4/5/2010 9:22:03 AM
   of 1182
 
Biotech Calendar: Key Dates for April

April 7
The U.S. Food and Drug Administration convenes an advisory panel to discuss Forest Labs'(FRX) Daxas for chronic obstruction pulmonary disease. The FDA's briefing documents should be posted to the agency's web site on April 5.

April 8
Celgene(CELG) analyst/investor day.
Lexicon Pharmaceuticals(LXRX) analyst/investor day.

April 9
Cell Therapeutics(CTIC) annual shareholders meeting.

April 10-17
American Academy of Neurology annual meeting.

Data presentations expected from
Genzyme(GENZ),
Acadia Pharmaceuticals(ACAD) and
Acorda Therapeutics(ACOR), among others.

April 13-17
AMAG Pharmaceuticals(AMAG) presents Feraheme data at National Kidney Foundation meeting.

April 14-18

European Association for the Study of the Liver (EASL) annual meeting.

Hepatitis C data expected from
Vertex Pharmaceuticals(VRTX),
Idenix Pharmaceuticals(IDIX),
Pharmasset(VRUS) and
Anadys(ANDS),
among others.

April 17-21
American Association for Cancer Research annual meeting.

Data presentations expected from

Cyclacel Pharmaceuticals(CYCC),
Dendreon(DNDN) and
Peregrine Pharmaceuticals(PPHM),
among others.

April 18
FDA approval decision date for OSI Pharmaceuticals'(OSIP) Tarceva in first-line non-small cell lung cancer.

April 22
FDA convenes advisory panel to review Acura Pharmaceuticals'(ACUR) abuse-resistant pain drug Acurox.

April 23
FDA approval decision date for Cell Therapeutics' pixantrone for non-Hodgkin's lymphoma.

April 30
FDA approval decision date for Pozen's(POZN) pain drug Vimovo.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on Twitter.

thestreet.com

CRACKER_BIO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News